🟢 82/100

This product is generally safe

  • Folate: 833mg is 833.0× the Tolerable Upper Intake Level (1.0mg)
  • Contains proprietary blend — exact ingredient amounts not disclosed
  • 80% of ingredients have research evidence
C Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Safety Alerts

⚠️ Folate: 833mg is 833.0× the Tolerable Upper Intake Level (1.0mg)
ℹ️ Contains proprietary blend — exact ingredient amounts not disclosed

Label Data

1 Capsule(s) Serving Size
60 Servings
Botanical with Nutrients Product Type
80% Evidence Coverage

Supplement Facts — Evidence Check

20 mcg (17% DV)
✅ Within RDA (0.2× RDA of 0.12 mg) 📚 273 studies (Tier A: 9, B: 175)
RDA 0.12mg This product: 0.02mg
4 mg (235% DV)
📊 3.1× RDA — above typical dose (UL: 100 mg) 📚 113 studies (Tier A: 3, B: 35)
RDA 1.3mg This product: 4mg UL 100mg
833 mcg DFE (208% DV)
⚠️ Exceeds Tolerable Upper Intake Level by 833.0× (UL: 1.0 mg) 📚 225 studies (Tier A: 10, B: 105)
RDA 0.4mg This product: 833mg UL 1.0mg
12 mcg (500% DV)
📊 5.0× RDA — above typical dose 📚 138 studies (Tier A: 1, B: 44)
RDA 0.0024mg This product: 0.012mg
Proprietary Blend
409 mg

Other Ingredients

Capsule Magnesium Stearate

Label Claims — Verification

All Other
Structure/Function
All Other (100% of products) Structure/Function (84% of products) Nutrient (73% of products)

Target Groups

Adult (18 - 50 Years) Kosher

Product Information

📋 Directions for Use

Suggested Use: Take 1 capsule with a meal two times daily.

⚠️ Warnings & Precautions

Pregnant or lactating women or persons taking any prescription medication should consult their health care professional prior to taking this supplement.

Do not use if inner seal is missing or damaged.

🧪 Formulation Notes

Ko Pareve (Kosher)

Circulatory system support Helps maintain healthy blood vessels

Cardio Assurance with Resveratrol

Guaranteed pure

Additional Information

Bottle made from 100% post consumer recycled material. We are committed to you and our planet. Scan to learn more. We source the world's purest ingredients, no matter where they are grown, to ensure the active nutrients are delivered just as nature intended.

Ko Pareve (Kosher)

New look! Same great product

Product Details

UPC / SKU 0 99904 00553 2
DSLD Entry Date 2022-10-24
Product Type Botanical with Nutrients
Form Capsule
DSLD ID 278037
Data Updated 2026-04-11

Research Evidence

332 Research Sources
59 Avg Quality Score
220 Meta Analysis
56 Systematic Review
30 Rct
16 Clinical Trial
3 Guideline
3 Regulatory Source
1 Narrative Review
1 Other
1 Openfda Safety
A Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
Meta Analysis The Cochrane database of systematic reviews 2014
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2017
A Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2016
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2020
A Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2025
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2018
A Antiplatelet agents and anticoagulants for hypertension
Systematic Review The Cochrane database of systematic reviews 2022
A Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Meta Analysis The Cochrane database of systematic reviews 2012
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2013
A Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Meta Analysis The Cochrane database of systematic reviews 2014
View all evidence for Vitamin K →

Compare Similar Products

View all Vitamin K products →